Comparative effect of physical exercise versus statins on improving arterial stiffness in patients with high cardiometabolic risk: A network meta-analysis.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
30
06
2020
accepted:
22
01
2021
revised:
02
03
2021
pubmed:
17
2
2021
medline:
29
6
2021
entrez:
16
2
2021
Statut:
epublish
Résumé
The comparative analysis of the effect of several doses of statins against different intensities of physical exercise on arterial stiffness (a measure of cardiovascular risk) could shed light for clinicians on which method is most effective in preventing cardiovascular disease (CVD) and be used to inform shared decision-making between doctors and patients. This study was aimed at analyzing the effect, in high cardiometabolic risk patients, of different statins doses and exercise intensities on arterial stiffness (a measure of cardiovascular risk) by integrating all available direct and indirect evidence in network meta-analyses. We systematically searched MEDLINE, Embase, SPORTDiscus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science databases from their inception to February 28, 2020; for unpublished trials, we also searched ClinicalTrials.gov. We searched for studies concerning the effect of statins or physical exercise on arterial stiffness, measured by pulse wave velocity (PWV). For methodological quality assessment, Cochrane Collaboration's tool for assessing risk of bias (RoB2) was used. A network geometry graph was used to assess the strength of the evidence. Comparative evaluation of the interventions effect was performed by conducting a standard pairwise meta-analysis and a network meta-analysis (NMA) for direct and indirect comparisons between interventions and control/nonintervention. A total of 22 studies were included in the analyses (18 randomized controlled trials (RCTs) and 4 nonrandomized experimental studies), including 1,307 patients with high cardiometabolic risk from Asia (3 studies), Oceania (2 studies), Europe (10 studies), North America (5 studies), and South America (2 studies). The overall risk of bias assessed with RoB2 was high in all included studies. For standard pairwise meta-analysis and NMA, high-intensity exercise versus control (mean difference (MD) -0.56; 95% CI: -1.01, -0.11; p = 0.015 and -0.62; 95% CI: -1.20, -0.04; p = 0.038, respectively) and moderate statin dose versus control (MD -0.80, 95% CI: -1.59, -0.01; p = 0.048 and -0.73, 95% CI: -1.30, -0.15; p = 0.014, respectively) showed significant MDs. When nonrandomized experimental studies were excluded, the effect on high-intensity exercise versus control and moderate statin dose versus was slightly modified. The main limitation of this study was that the magnitude of the effect of the exercise interventions could be underestimated due to regression toward the mean bias because the baseline cardiometabolic risk profile of patients in the physical exercise intervention trials was healthier than those in the statins ones; consequently, more modest improvements in physical exercise interventions compared to statins interventions can be expected. Additionally, we might consider as limitations the small study sizes, the heterogeneous patient groups, the focus on a proxy endpoint (PWV), and the high risk of bias. In this NMA, we found that although many patients could benefit from statins for reducing CVD risk, our results support that, considering the beneficial effects of high-intensity exercise on arterial stiffness, it would be worthwhile to refocus our attention on this type of exercise as an effective tool for the prevention of CVD. PROSPERO CRD42019123120.
Sections du résumé
BACKGROUND
The comparative analysis of the effect of several doses of statins against different intensities of physical exercise on arterial stiffness (a measure of cardiovascular risk) could shed light for clinicians on which method is most effective in preventing cardiovascular disease (CVD) and be used to inform shared decision-making between doctors and patients. This study was aimed at analyzing the effect, in high cardiometabolic risk patients, of different statins doses and exercise intensities on arterial stiffness (a measure of cardiovascular risk) by integrating all available direct and indirect evidence in network meta-analyses.
METHODS AND FINDINGS
We systematically searched MEDLINE, Embase, SPORTDiscus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science databases from their inception to February 28, 2020; for unpublished trials, we also searched ClinicalTrials.gov. We searched for studies concerning the effect of statins or physical exercise on arterial stiffness, measured by pulse wave velocity (PWV). For methodological quality assessment, Cochrane Collaboration's tool for assessing risk of bias (RoB2) was used. A network geometry graph was used to assess the strength of the evidence. Comparative evaluation of the interventions effect was performed by conducting a standard pairwise meta-analysis and a network meta-analysis (NMA) for direct and indirect comparisons between interventions and control/nonintervention. A total of 22 studies were included in the analyses (18 randomized controlled trials (RCTs) and 4 nonrandomized experimental studies), including 1,307 patients with high cardiometabolic risk from Asia (3 studies), Oceania (2 studies), Europe (10 studies), North America (5 studies), and South America (2 studies). The overall risk of bias assessed with RoB2 was high in all included studies. For standard pairwise meta-analysis and NMA, high-intensity exercise versus control (mean difference (MD) -0.56; 95% CI: -1.01, -0.11; p = 0.015 and -0.62; 95% CI: -1.20, -0.04; p = 0.038, respectively) and moderate statin dose versus control (MD -0.80, 95% CI: -1.59, -0.01; p = 0.048 and -0.73, 95% CI: -1.30, -0.15; p = 0.014, respectively) showed significant MDs. When nonrandomized experimental studies were excluded, the effect on high-intensity exercise versus control and moderate statin dose versus was slightly modified. The main limitation of this study was that the magnitude of the effect of the exercise interventions could be underestimated due to regression toward the mean bias because the baseline cardiometabolic risk profile of patients in the physical exercise intervention trials was healthier than those in the statins ones; consequently, more modest improvements in physical exercise interventions compared to statins interventions can be expected. Additionally, we might consider as limitations the small study sizes, the heterogeneous patient groups, the focus on a proxy endpoint (PWV), and the high risk of bias.
CONCLUSIONS
In this NMA, we found that although many patients could benefit from statins for reducing CVD risk, our results support that, considering the beneficial effects of high-intensity exercise on arterial stiffness, it would be worthwhile to refocus our attention on this type of exercise as an effective tool for the prevention of CVD.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42019123120.
Identifiants
pubmed: 33591983
doi: 10.1371/journal.pmed.1003543
pii: PMEDICINE-D-20-03097
pmc: PMC7924736
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003543Subventions
Organisme : Department of Health
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Hypertens Res. 2010 Jun;33(6):627-32
pubmed: 20379194
BMJ. 2008 Aug 29;337:a1331
pubmed: 18757996
J Clin Epidemiol. 2011 Apr;64(4):380-2
pubmed: 21185693
J Hum Hypertens. 2002 Oct;16(10):705-10
pubmed: 12420194
Med Clin (Barc). 2016 Sep 16;147(6):262-6
pubmed: 27040178
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
J Hypertens. 2015 Jul;33(7):1438-45
pubmed: 25827429
CMAJ. 2006 Mar 28;174(7):961-74
pubmed: 16567757
J Hum Hypertens. 2015 Aug;29(8):502-10
pubmed: 25252689
Metabolism. 2009 Jul;58(7):1030-8
pubmed: 19411087
Hypertension. 2009 Oct;54(4):763-8
pubmed: 19687343
Mayo Clin Proc. 2015 Oct;90(10):1314-9
pubmed: 26434957
Int J Cardiol. 2017 Jan 15;227:338-341
pubmed: 27839806
Clin Exp Hypertens. 2018;40(7):601-608
pubmed: 29420075
Med Sci Sports Exerc. 2011 Jul;43(7):1334-59
pubmed: 21694556
J Atheroscler Thromb. 2010 Mar 31;17(3):235-41
pubmed: 20032570
Can Fam Physician. 2002 Jan;48:72-80
pubmed: 11852615
Curr Vasc Pharmacol. 2018;16(4):393-400
pubmed: 28669329
Mayo Clin Proc. 2015 Oct;90(10):1338-47
pubmed: 26434961
J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27
pubmed: 20338492
J Clin Epidemiol. 2011 Feb;64(2):163-71
pubmed: 20688472
J Clin Hypertens (Greenwich). 2018 Jan;20(1):11-18
pubmed: 29106772
Ann Intern Med. 2013 Jul 16;159(2):130-7
pubmed: 23856683
Am J Med. 2018 Feb;131(2):148-155
pubmed: 28864036
Am J Kidney Dis. 2010 Jan;55(1):88-99
pubmed: 19932545
Diab Vasc Dis Res. 2019 Jan;16(1):38-46
pubmed: 30328360
Int J Cardiol. 2015 Jan 20;179:269-74
pubmed: 25464463
J Diabetes Res. 2015;2015:846807
pubmed: 26064990
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Nutr Metab Cardiovasc Dis. 2007 Jul;17(6):436-41
pubmed: 17134956
Am J Hypertens. 2013 May;26(5):608-16
pubmed: 23449607
PLoS One. 2014 Oct 15;9(10):e110034
pubmed: 25333969
J Gen Intern Med. 2012 Nov;27(11):1453-9
pubmed: 22610907
Mayo Clin Proc. 2013 Dec;88(12):1446-61
pubmed: 24290119
JAMA. 2016 Nov 15;316(19):2008-2024
pubmed: 27838722
BMJ. 2011 Jul 15;343:d4141
pubmed: 21765112
Am J Cardiol. 2009 Apr 1;103(7):972-7
pubmed: 19327425
Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123
pubmed: 30559236
Medicine (Baltimore). 2019 May;98(20):e15484
pubmed: 31096447
Hypertension. 2008 Jun;51(6):1651-7
pubmed: 18426996
Circulation. 2003 Sep 30;108(13):1534-6
pubmed: 14517147
J Am Coll Cardiol. 2014 Feb 25;63(7):636-646
pubmed: 24239664
Circulation. 2006 Feb 7;113(5):664-70
pubmed: 16461839
BMJ. 2001 Jul 14;323(7304):101-5
pubmed: 11451790
BMJ. 2014 Jul 17;349:g3743
pubmed: 25035309
Am J Cardiol. 2012 Apr 1;109(7):1005-10
pubmed: 22244035
J Hum Hypertens. 2013 May;27(5):335-9
pubmed: 22951625
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623
Eur J Prev Cardiol. 2017 Jun;24(9):907-916
pubmed: 28436720
J Appl Physiol (1985). 2014 Jun 1;116(11):1396-404
pubmed: 24744384
PLoS One. 2013 Oct 03;8(10):e76654
pubmed: 24098547
J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232
pubmed: 30894318
Cardiorenal Med. 2019;9(6):391-399
pubmed: 31597151
Eur Heart J. 2010 Oct;31(19):2338-50
pubmed: 20530030
Scand J Med Sci Sports. 2015 Dec;25 Suppl 3:1-72
pubmed: 26606383